

Summary and conclusions

Breast cancer is the most common cancer of women, and its incidence is rising especially in developing countries, an estimated 1.7 million women will be diagnosed with breast cancer in 2020, a 26% increase from current levels, mostly in the developing world. Apoptosis is a form of programmed cell death that plays a critical role in the maintenance of tissue homeostasis. The dysregulation of apoptosis is a hallmark of cancer, with both the loss of pro-apoptotic signals and the gain of anti-apoptotic mechanisms contributing to tumorigenesis.

Among pharmacological agents, many cancer chemotherapeutic drugs are known to activate apoptotic mechanisms of tumor cell death; this may be a mechanism for current cancer treatment. Moreover, apoptosis has been proposed as a novel target for cancer chemoprevention.

Multiple stimuli such as ionizing radiations, DNA lesions, nitric oxide, hypoxia, chemotherapeutic agents, or oncogenic stimuli can activate p53. In response to activation it could induce different effects. p53 is a transcription factor involved in the control of cell cycle phase transition, in DNA repair, and in induction of senescence, apoptosis.

Survivin, is a small 16.5 kDa protein belonging to the inhibitor-of-apoptosis (IAP) family. Interest in survivin stems from its pattern of expression: it is upregulated in almost all tumour types while being minimally expressed in terminally differentiated tissues. Moreover, it plays a key role in both apoptosis and control of cell-cycle progression.

DNA fragmentation is the hallmark of apoptosis, Correlations between the occurrence of cell-free DNA in blood of tumor patients and malignancy of their disease were reported. DNA integrity and DNA integrity index may vary between healthy individuals and cancer.

Cytc is a multi-functional enzyme that is involved in life and death decisions of the cell. The intrinsic pathway of apoptosis is mediated by various stimuli that cause the release of Cytc from mitochondria into the cytoplasm, triggering caspase activation.

Some *in vitro* studies have reported that vitamins A, C, and E, as well as carotenoids, can enhance the effectiveness of chemotherapy.

Aim of the work:

The present study aimed to evaluate the possible effects of vitamin A and E supplementation during chemotherapy on apoptosis in breast cancer patients.

Subjects and methods:

This study included forty-five breast cancer subjects; they were divided into two groups: control group (Group Ia & Ib), 20 patients in this group received 6 cycles of chemotherapy, and the vitamins-treated group (Group IIa & IIb), 25 patients in this group received a daily vitamins A and E supplementation along with the chemotherapeutic course. From each patient in both groups, a blood sample was collected before starting the chemotherapy, and another sample was collected two weeks after the last cycle of chemotherapy.

The following markers were assessed for in sera of all patients in the two studied groups:

- Concentration of p53.
- Level of Survivin.
- Determination of free circulating DNA.
- Level of cytochrome c.

The results of this study revealed that:

- p53 protein showed a significant increase in its level in the control group and vitamins-treated groups after chemotherapy (Group Ib & IIb) as compared to its level in the corresponding groups before chemotherapy (Group Ia & Ib).
- The level of serum survivin concentration didn't show any significant difference when comparing Group Ib with Group Ia. While, it showed a significant decrease when comparing Group IIb with both groups IIa & Ib.
- After chemotherapy, the apoptotic bands of cDNA in the vitamins-treated group were more intense and predominant rather than that in the control group.

- The level of serum cytochrome C concentration didn't show any significant difference when comparing Group Ib with Group Ia, and when comparing Group IIb with IIa. However, its level showed a significant increase when comparing Group IIb with Ib.

From all these results obtained in this work, we can conclude that:

- (1) Apoptosis may not be the most dominant form of cell death for solid tumors, it might be due to the fact that chemotherapy is not specifically designed to induce apoptosis, but it may result in apoptosis as a secondary effect, caused by induced cellular damage.
- (2) Enhancement of the apoptotic potential of conventional breast cancer therapies may thus increase the overall tumor cell death.
- (3) The combination of vitamins with chemotherapy showed a strong synergistic activation of apoptosis.
- (4) Vitamin A and E supplementation exerts its apoptotic effect in cancer cells by various mechanisms, through down-regulation of some inhibitors of apoptosis proteins, such as survivin, rather than up-regulation of tumor suppressor proteins, such as p53. It is also found that they act through activation of intrinsic "mitochondrial" pathway, which results in cytochrome c release, and subsequent activation of caspases cascade.

From all results found in this study, we can recommend the followings:

(A) Recommendation for research:

- (1) Further studies with larger number of patients and different doses of vitamins and more biochemical parameters are recommended to obtain more definite results.
- (2) Studying the action of various promising drug candidates and also comparing their efficacy and therapeutic index in combination with chemotherapy/radiotherapy, would be another worth while pursuit.
- (3) Survivin-directed therapies could be incorporated into a broad spectrum of oncological practice either as single agents or, more likely, in combination with existing chemotherapeutics, particularly those that exert their effects through apoptosis.

(B) Recommendation for public health:

- (1) It is a good recommendation to provide vitamin supplements, which act as an attractive public health strategy for the prevention of cancer.
- (2) A diet including different forms of vegetables and fruits which contain large amounts of vitamin is highly recommended to act as strategy to decrease the incidence of breast cancer.

References

- 1) Tfayli A, Temraz S, Abou Mrad R, Shamseddine A. Breast Cancer in Low- and Middle-Income Countries: An Emerging and Challenging Epidemic. *J of Oncol*, 2010; 1-5.
- 2) Porter P. ““Westernizing” women’s risks? Breast cancer in lower-income countries”. *The New England J of Medicine*, 2008; 358: 213–6.
- 3) Curado MP, Edwards B, Shin HR, Storm H. Cancer Incidence in Five Continents. International Agency for Research on Cancer (IARC), 2007; IX, IARC Scientific Publications no. 160, Lyon, France.
- 4) The Lancet. “Breast cancer in developing countries”. *The Lancet*, 2009; 374: 1567–2131.
- 5) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN, 2008, *Int J Cancer*.
- 6) Annual report. Alexandria, Cancer Registry Department of Bioinformatics and Medical Statistic. Medical Research Institute, Alexandria University, Egypt.
- 7) Sasieni PD, Shelton J, Ormiston-Smith NJ, Thomson CS, Silcocks PB. What is the lifetime risk of developing cancer?. The effect of adjusting for multiple primaries. *Br J Cancer*, 2011; 105: 460-5.
- 8) Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson W F , et al. Established breast cancer risk factors by clinically important tumour characteristics. *Br J Cancer*, 2006; 360: 187-95.
- 9) Collaborative Group on Hormonal Factors in Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. *Lancet*, 2002; 360: 187-95.
- 10) Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast Cancer Res*, 2006; 8: 1-11.
- 11) Ewertz M, Duffy SW, Adami HO, Kvåle G, Lund E, Meirik O, et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. *Int J Cancer*, 1990; 46: 597-603.
- 12) Shantakumar S, Terry MB, Teitelbaum SL, Britton JA, Millikan RC, Moorman PG, et al. Reproductive factors and breast cancer risk among older women. *Breast Cancer Res Treat*, 2007; 102: 365-74.
- 13) Ji J, Forsti A, Sundquist J, Hemminki K. Risks of breast, endometrial and ovarian cancers after twin births. *Endocri Relat Cancer*, 2007; 14:703-11.

- 14) Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet*, 1997; 350: 1047-59.
- 15) Key T, Appleby P, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst*, 2002; 94: 606-16.
- 16) Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. *J Natl Cancer Inst*, 2007; 25: 1482-8.
- 17) Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*, 2009; 101: 48-60.
- 18) Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*, 1996; 347: 1713-27.
- 19) Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. *The Lancet*, 2003; 362: 419-27.
- 20) Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis. *Lancet Oncol*, 2006; 7: 910-18.
- 21) Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen-progestin replacement therapy and breast cancer risk. *JAMA*, 2000; 283: 485-91.
- 22) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 without the disease. *Lancet*, 2001; 358: 1389-99.
- 23) Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. *Int J Cancer*, 1997; 71: 800-9.
- 24) El-Debaky FE, Azab NI, Alhussein NF, Eliwa SK, and Musalam HR. Breast cancer gene 1 (BRCA 1) mutation in female patients with or without family history in Qalubia Governorate. *J Am Sci*, 2011; 7: 82-93.
- 25) Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*, 2007; 99: 1178-87.
- 26) McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*, 2006; 15: 1159-69.

- 27) Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degen AC, Ghosh K, et al. Benign breast disease and the risk of breast Cancer. *N Engl J Med*, 2005; 353: 229-37.
- 28) Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. *Bmj*, 2007; 335: 1134.
- 29) Key TJ, Appleby PN, Reeves GK, Roddam A. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst*, 2003; 95: 1218-26.
- 30) Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA. A prospective study of age-specific physical activity and premenopausal breast cancer. *J Natl Cancer Inst*, 2008; 100: 728-37.
- 31) Chan MF, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, et al. Usual physical activity and endogenous sex hormones in postmenopausal women: the European prospective investigation into cancer-norfolk population study. *Cancer Epidemiol Biomarkers Prev*, 2007; 16: 900-5.
- 32) Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard, et al. Carcinogenicity of alcoholic beverages. *Lancet Oncol*, 2007; 8: 292-3.
- 33) Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. *J Natl Cancer Inst*, 2009; 101: 296-305.
- 34) Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature. *Br J Cancer*, 2003; 89: 1672-85.
- 35) Thiebaut AC, Kipnis V, Chang SC. Dietary fat and post menopausal breast cancer in the National Institutes of Health -AARP Diet and Health Study Cohort. *J Natl Cancer Inst*, 2007; 99: 451-62.
- 36) Bingham S, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are imprecise methods obscuring a relation between fat and breast cancer?. *Lancet*, 2003; 362: 212-4.
- 37) Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Nightwork and breast cancer risk: a systematic review and meta-analysis. *Eur J Cancer*, 2005; 41: 2023-32.
- 38) Kakizaki M, Kuriyami S, Sone T, Ohmori-Mastuda K, Hozawa A, Nakaya N, et al. Sleep duration and breast cancer: the Ohsaki Cohort study. *Br J Cancer*, 2008. 99: 1502-5.
- 39) Schernhammer ES, Ankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the nurses' health study cohort. *Cancer Epidemiol Biomarkers Prev*, 2009; 18: 74-9.
- 40) Straif K, Baan R, Grosse Y, Secretan B, El-Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. *Lancet Oncol*, 2007; 8: 1065-6.

- 41) John EM, Phipps AI, Knight JA, Milne RL, Dite GS, Hopper JL, et al. Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry. *Int J Cancer*, 2007; 121: 386-94.
- 42) Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, et al. Breast cancer after treatments of Hodgkin's lymphoma: Risk factors that really matter. *Int J Radiat Oncol Biol Phys*, 2008; 72: 1291-7.
- 43) Taylor Aj, Winter DL, Stiller CA, Murphy M, Hawkins MM. Risk of breast cancer in survivors of childhood Hodgkin's disease in Britain: a population based study. *Int J Cancer*, 2007; 120: 384-91.
- 44) Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. *Br J Cancer*, 2010;102: 220–6.
- 45) Fawzy S, Sallam M, Awad NM. Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. *Clin Biochem*, 2008; 41: 486-92.
- 46) Magnusson M, Hoglund P, Johansson K, Jo-nssond C, Killander F, Malmstrom P, et al. Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, double-blind, placebo-controlled randomized clinical trial (Ptx-5). *Euro J CANCER*, 2009; 45: 2488 – 95.
- 47) Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial. *Acta Oncol*, 1992; 31: 231–6.
- 48) Saito I. Chemistry of drug-induced DNA lesions. *Toxicol Lett*, 1993; 67: 3–15.
- 49) Wallace S, Houten BV, Kow YW. DNA damage: effects on DNA structure and protein recognition, in: *Proceedings of a Conference, Burlington, Vermont, Ann N Y Acad Sci*, 1994; 29:1–385.
- 50) Jackson SP. Sensing and repairing DNA double-strand breaks. *Carcinogen*, 2002; 23: 687–96.
- 51) Zoli W, Ulivi P, Tesei A, Fabbri F, Rosetti M, Maltoni R, et al. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. *Breast Cancer Res*, 2005; 7: 681–9.
- 52) Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. *Proc Natl Acad Sci*, 1999; 96: 10764–9.
- 53) Czeczuga-Semeniuk E, Wołczyn 'ski S, Da browska M, Dzie cioł J, and Anchim T. The effect of doxorubicin and retinoids on proliferation, necrosis and apoptosis in MCF-7 breast cancer cells. *Folia Histochemica et Cytobiologica*, 2004; 42: 221-7.
- 54) Rubens RD. Single-agent chemotherapy. In: *Medical management of breast cancer*. Powles TJ, Smith IE, Martin Dunitz. London, 1999; 131-7.

- 55) Falkson G, Falkson CI, Falkson H. Combination chemotherapy. In: Medical management of breast cancer. Powles TJ, Smith IE, Martin Dunitz. London, 1992: 139-51.
- 56) Zunino F, Gambetta R, DiMarco A. The inhibition *in vitro* of DNA polymerase and RNA polymerases by daunomycin and adriamycin. *Biochem Pharmacol*, 1975; 24: 309-11.
- 57) Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. *Cancer Res*, 1976; 36: 2891-5.
- 58) Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. *Science*, 1984; 226: 466-8.
- 59) Schmitt CA. Senescence, apoptosis and therapy—cutting the life- lines of cancer. *Nat Rev Cancer*, 2003; 3: 286–95.
- 60) Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer— implications for therapy. *Semin Oncol*, 2004; 31: 90–119.
- 61) Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. *Lancet Oncol*, 2003; 4: 721–9.
- 62) Waxman DJ, Schwartz PS. Harnessing apoptosis for improved anticancer gene therapy, *Cancer Res*, 2003; 63: 8563–72.
- 63) Sun SY, Hail N, Lotan R, Apoptosis as a novel target for cancer chemoprevention. *J Natl Cancer Inst*, 2004; 96: 662–72.
- 64) Degterev A, Boyce M, Yuan J. A decade of caspases. *Oncogene*, 2003; 22: 8543-67.
- 65) Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*, 2000; 100:57-70.
- 66) Ziegler DS, Kung AL. Therapeutic targeting of apoptosis path- ways in cancer. *Curr Opin Oncol*, 2008; 20: 97-103.
- 67) Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. *Cell Death Differ*, 2003; 10: 26-35.
- 68) Tsujimoto Y. Bcl-2 family of proteins. life-or-death switch in mitochondria. *Biosci Rep*, 2002; 22: 47-58.
- 69) Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. *J Pharmacol Exp Ther*, 2001; 298: 873-8.
- 70) Hail JN. Mitochondria: a novel target for the chemoprevention of cancer. *Apoptosis*, 2005; 10: 687–705.
- 71) Crighton D, Ryan KM. Splicing DNA-damage responses to tumour cell death. *Biochim Biophys Acta*, 2004; 1705: 3–15.
- 72) Lacroix M, Toillon RA, Leclercq G. “p53 and breast cancer, an update,” *Endocrine-Related Cancer*, 2006; 13: 293–325.

- 73) Slee EA, O'Connor DJ, Lu X. "To die or not to die: how does p53 decide?". *Oncogene*, 2004; 23: 2809–18.
- 74) Soussi T. "The p53 tumor suppressor gene: from molecular biology to clinical investigation,". *Annals of the New York Academy of Sciences*, 2000; 910:121–37.
- 75) Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn, J, et al. "The C terminus of p53 binds the N-terminal domain of MDM2". *Nature Structural & Molecular Biology*, 2010; 178: 982–9.
- 76) Lohrum MA, Woods DB, Ludwig RL, Alint EB, Vousden KH. "C-terminal ubiquitination of p53 contributes to nuclear export". *Molecular and Cellular Biology*, 2001; 21: 8521–32.
- 77) He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, et al. "Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities". *Oncogene*, 2005, 24; 18: 2929–43.
- 78) Cox ML, Meek DW. "Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli". *Cellular Signalling*, 2010; 22: 564–71.
- 79) Wiesmuller L. "Genetic stabilization by p53 involves growth regulatory and repair pathways". *J of Biomed & Biotech*, 2001; 1: 7–10.
- 80) Ocker M, Schneider-Stock R. "Histone deacetylase inhibitors: signalling towards p21cip1/waf1". *The Int J of Biochem & Cell Biol*, 2007; 39: 1367–74.
- 81) Helton ES, Chen X. "p53 modulation of the DNA damage response." *J of Cellular Biochem*, 2007; 100: 883–96.
- 82) Ben-Porath I, Weinberg RA. "The signals and pathways activating cellular senescence". *The Int J of Biochem & Cell Biol*, 2005; 37: 961–76.
- 83) Wahl GM, Carr AM. "The evolution of diverse biological responses to DNA damage: insights from yeast and p53." *Nature Cell Biol*, 2001; 3: 277–86.
- 84) Ryan KM. "p53 and autophagy in cancer: guardian of the genome meets guardian of the proteome". *Euro J of Cancer*, 2011; 47: 44–50.
- 85) Mihara M, Erster S, Zaika A. "p53 has a direct apoptogenic role at the mitochondria". *Mol Cell*, 2003; 11: 577–90.
- 86) Rodier F, Campisi J, Bhaumik D. "Two faces of p53: aging and tumor suppression". *Nucleic Acids Res*, 2007; 35: 7475–484.
- 87) Harris SL, Levine AJ. "The p53 pathway: positive and negative feedback loops". *Onco*, 2005; 17: 2899–908.
- 88) Teodoro JG, Evans SK, Green MR. "Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome." *J of Mol Med*, 2007; 85: 1175–86.

- 89) Takahashi Y, Bucana CD, Cleary KR, Ellis LM. "p53, vessel count, and vascular endothelial growth factor expression in human colon cancer". *Int J of Cancer*, 1998; 79: 34–8.
- 90) Wang XQ, Stanbridge EJ, Lao X, Cai Q, Fan ST, Redpath JL. "p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 arrest". *Rad Res*, 2007; 168: 706–15.
- 91) Li T, Santockyte R, Shen RF, Tekle E, Wang G, Yang DC, et al. "Expression of SUMO- 2/3 induced senescence through p53- and pRB-mediated pathways". *The J of Biol Chem*, 2006; 281: 36221–27.
- 92) Giono LE, Manfredi JJ. "Mdm2 plays a positive role as an effector of p53-dependent responses". *Cell Cycle*, 2007; 17: 2143–47.
- 93) Toledo F, Wahl GM. "Regulating the p53 pathway: *in vitro* hypotheses, *in vivo* veritas". *Nature Reviews Cancer*, 2006; 12: 909–23.
- 94) Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. "TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes". *Oncogene*, 2007; 26: 2157–65.
- 95) Broshand R, Rotter V. "When mutants gain new powers: news from the mutant p53 field". *Nat Reviews Cancer*, 2009; 9: 701–13.
- 96) Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. "Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms". *Science*, 1990; 250: 1233–38.
- 97) Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer*, 2005; 5: 231-7.
- 98) Fulda S. Tumor resistance to apoptosis. *Int J Cancer*, 2009; 124: 511-5.
- 99) Srinivasula SM, Ashwell JD. IAPs: what's in a name?. *Mol Cell*, 2008; 30: 123-35.
- 100) LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. *Oncogene*, 2008; 27: 6252-75.
- 101) Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med*, 1997;3: 917–21.
- 102) Fukuda S, Melus LM. *Mol Cancer Ther*, 2006; 5: 1087–98.
- 103) Mita AC, Mita MM, Nawrocki St, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel targets for cancer therapeutics. *Clin Cancer Res*, 2008; 14: 5000–5.
- 104) Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. *Ann Oncol*, 2006; 17: 597-604.

- 105) Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. *Clin Cancer Res*, 2003; 9: 4914-25.
- 106) Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, et al. Expression of IAP family proteins in esophageal cancer. *Exp Mol Pathol*, 2004; 76: 253-9.
- 107) Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR. Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. *Int J Cancer*, 2007; 120: 2344-52.
- 108) Gordon G, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, et al. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. *J Pathol*, 2007; 211: 447-54.
- 109) Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. *Cancer Res*, 2003; 63: 6815-24.
- 110) Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. *Cancer Res*, 2004; 64: 3006-8.
- 111) Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. *J Clin Invest*, 2004; 114: 1117-27.
- 112) Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, Prouser T, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. *Cancer Res*, 2006; 66: 1730-9.
- 113) Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. *Cancer Res*, 2008; 68: 9384-93.
- 114) Galban S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A, et al. Cytoprotective effects of IAPs revealed by a small molecule antagonist. *Biochem J*, 2009; 417: 765-7.
- 115) Ueda Y, Nakagawa T, Kubota T, Ido K, Sato K. Glioma cells under hypoxic conditions block the brain microvascular endothelial cell death induced by serum starvation. *J Neurochem*, 2005; 95: 99-110.
- 116) Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. *Am J Pathol*, 2008; 173: 575-85.
- 117) Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. *Urology*, 2007; 69: 34-7.

- 118) Prager GW, Mihaly J, Brunner PM, Koshelnick Y, Hoyer-Hansen G, Binder BR: Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. *Blood*, 2009; 113: 1383-90.
- 119) Johnson ME, Howerth EW. Survivin: A Bifunctional Inhibitor of Apoptosis Protein. *Vet Pathol*, 2004; 41:599–607.
- 120) Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP, et al. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. *Nat Struct Biol*, 2000; 7:602–8.
- 121) Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. *Carcinogenesis*, 2007; 28:1133-9.
- 122) Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in insitu and invasive breast cancer relates to COX-2 expression and DCIS recurrence. *Br J Cancer*, 2006; 94: 253-8.
- 123) Yie SM, Luo B, Ye NY, Xie K, Ye SR. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. *Clin Exp Metastasis*, 2006; 23: 279-89.
- 124) Guney N, Soydine HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum and urine survivin levels in breast cancer. *Med Oncol*, 2006; 23: 335-9.
- 125) Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. *Cancer Treat Rev*, 2009; 35: 553–62.
- 126) Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. *Cancer Lett*, 2007; 2491:49–60.
- 127) Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. *Nat Rev Cancer*, 2008;81:61–70.
- 128) Zaffaroni N, Daidone M. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. *Drug Resist Updat*, 2002; 5:65-72.
- 129) Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, et al. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. *Mol Cancer*, 2009, 8: 43.
- 130) Moriai R, Tsuji N, Moriai M, Kobayashi D, Watanabe N. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. *Breast Cancer Res Treat*, 2009; 117: 261-71.
- 131) Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. *Anticancer Res*, 2009; 29: 223-8.

- 132) Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, et al. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. *Cancer Sci*, 2004; 95: 44-51.
- 133) Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, et al. Survivin as a radioresistance factor, prognostic and therapeutic target for radiotherapy in rectal cancer. *Cancer Res*, 2005; 65: 4881-7.
- 134) Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, et al. BKM1740, an acyltyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. *Clin Cancer Res*, 2008; 14: 6198-206.
- 135) Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. *Cancer Res*, 1999; 59: 6097-102.
- 136) Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Res*, 1998; 58: 5315-20.
- 137) Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. *Oncogene*, 2000; 19: 1346-53.
- 138) Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. *Oncogene*, 2002; 21: 2613-22.
- 139) Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. *Cell Mol Life Sci*, 2002; 598: 1406-12.
- 140) Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. *J Pediatr Surg*, 2006; 41: 1431-40.
- 141) Wright ME, Han DK, Hockenberry DM. Caspase-3 and inhibitor of apoptosis protein(s) interactions in *Saccharomyces cerevisiae* and mammalian cells. *FEBS Lett*, 2000; 481: 13-8.
- 142) Grossman D, Kim PJ, Blanc-Brude OP, Brash DE, Tognin S, Marchisio PC, et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. *J Clin Invest*, 2001; 107: 991-9.
- 143) Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. *Eur J Cancer*, 2002; 38: 2316-24.

- 144) Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. *Cancer Treat Rev*, 2007; 33: 203–12.
- 145) Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. *At Rev Mol Cell Biol*, 2002; 36: 401–10.
- 146) Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. *Proc Natl Acad Sci*, 1999; 96: 1457–62.
- 147) O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34-cdc2 phosphorylation of survivin. *Proc Natl Acad Sci*, 2000; 97: 13103–7.
- 148) Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. *Nat Cell Biol*, 1999; 18: 461–6.
- 149) Shin S, Sung BJ, Cho YS. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. *Biochemistry*, 2001; 40: 1117–23.
- 150) Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F, et al. Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. *Gastroenterology*, 2002; 123: 619–31.
- 151) Banks DP, Plescia J, Altieri DC, Chen J, Rosenberg SH, Zhang H et al. Survivin does not inhibit caspase-3 activity. *Blood*, 2000; 96: 4002–3.
- 152) Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. *Protein Sci*, 2008; 17: 1624–9.
- 153) Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. *EMBO Rep*, 2006; 7: 988–94.
- 154) Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. *EMBO J*, 2003; 22: 2729–40.
- 155) Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. *Oncogene*, 2007; 26: 7569–75.
- 156) Dohi T, Xia F, Altieri D. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. *Mol Cell*, 2007; 27: 17–28.
- 157) Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. *Cancer Sci*, 2008; 99: 1709–14.
- 158) Raj D, Liu T, Samadashwily G, Li F, Grossman D. Survivin repression by p53, Rb and E2F2 in normal human melanocytes. *Carcinogenesis*, 2008; 29: 194–201.

- 159) Delacour-Larose M, Thi MN, Dimitrov S, Molla A. Role of survivin phosphorylation by aurora B in mitosis. *Cell Cycle*, 2007; 6: 1878–85.
- 160) Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, et al. Regulation of survivin function by Hsp90. *Proc Natl Acad Sci*, 2003; 100: 13791–6.
- 161) Dhallan R, Guo X, Emche S, Damewood M, Bayliss P, Cronin M, et al. A non-invasive test for prenatal diagnosis based on fetal DNA present in maternal blood: a preliminary study. *Lancet*, 2007; 369: 474–81.
- 162) Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. *Biochim Biophys Acta*, 2007; 1775: 181–232.
- 163) Gormally E, Hainaut P, Caboux E, Airoidi L, Autrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: a prospective study. *Int J Cancer*, 2004; 111: 746–9.
- 164) Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. *Cancer Res*, 2001; 61: 4675–8.
- 165) Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res*, 2001; 61: 1659–65.
- 166) Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. *Mutat Res*, 2007; 635: 105–17.
- 167) Tong YK, Lo YMD. Diagnostic developments involving cell-free (circulating) nucleic acids. *Clin Chim Acta*, 2006; 363: 187–96.
- 168) Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. *J Clin Oncol*, 2004; 22: 4157–64.
- 169) Xue X, Zhu YM, Woll PJ. Circulating DNA and lung cancer. *Ann NY Acad Sci*, 2006; 1075: 154–64.
- 170) Khan S, Coulson JM, Woll PJ. Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases. *Int J Cancer*, 2004; 110: 891–5.
- 171) Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. *Clin Cancer Res* 1999; 5: 2297–303.
- 172) Chun FK, Muller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, et al. Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. *B J U Int*, 2006; 98: 544-8.

- 173) Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM, et al. Rapid clearance of fetal DNA from maternal plasma. *Am J Hum Genet*, 1999; 64: 218-24.
- 174) Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, et al . Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. *Clin Chem*, 2000; 46: 1078-84.
- 175) Minchin RF, Carpenter D, Orr RJ. Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. *J Pharmacol Exp Ther* 2001; 296: 1006-12.
- 176) Arends MJ, Morris RG, Wyllie AH. Apoptosis: The role of endonuclease. *Am J Pathol*, 1990; 136: 593–608.
- 177) Nagata S. Apoptotic DNA fragmentation. *Exp Cell Res*, 2000; 256: 12– 8.
- 178) Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H . Degradation of chromosomal DNA during apoptosis. *Cell Death Differ*, 2003; 10: 108– 16.
- 179) Dullea RG, Robinson JF, Bedford JS. Nonrandom degradation of DNA in human leukocytic cells during radiation-induced apoptosis. *Cancer Res*, 1999; 59: 3712-8.
- 180) Enari M, Sakahira H, Yokoyama H , Okawa K, Iwamatsu A, Nagata SA. Caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature*, 1998; 391: 43–50.
- 181) Los M, Neubuser D, Coy JF, Mozoluk M, Poustka A, Schulze-Osthoff K. Functional characterization of DNase X, a novel endonuclease in muscle cells. *Biochemistry*, 2000; 39: 7365–73.
- 182) Kunitz M. Isolation of crystalline deoxyribonuclease from beef pancreas. *Science* 1948; 108: 19–20.
- 183) Walker PR, Sikorska M. Endonuclease activities, chromatin structure, and DNA degradation in apoptosis. *Biochem Cell Biol*, 1994; 72: 615– 23.
- 184) Walker PR, Sikorska M. New aspects of the mechanism of DNA fragmentation in apoptosis. *Biochem Cell Biol*, 1997; 75: 287–99.
- 185) Peitsch MC, Polzar B, Stephan H, Crompton T, McDonald HR, Mannherz HG, et al. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). *EMBO J*, 1993; 12: 371–7.
- 186) Polzar B, Peitsch MC, Loos R, Tschopp J, Mannherz HG. Overexpression of deoxyribonuclease I (DNase I) transfected into COS-cells: Its distribution during apoptotic cell death. *Eur J Cell Biol*, 1993; 62: 397– 405.
- 187) Boulares AH, Zoltoski AJ, Sheriff ZA, Yakovlev AG, Smulson ME. The poly (ADP ribose) polymerase-regulated endonuclease NNA S1L3 is required for etoposide-induced

- internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells. *Cancer Res*, 2002; 62: 4439–44.
- 188) Boulares AH, Ren T. Mechanism of acetaminophen-induced apoptosis in cultured cells: Roles of caspase-3, DNA fragmentation factor, and the Ca²⁺ and Mg²⁺ endonuclease DNA S1L3. *Basic Clin Pharmacol Toxicol*, 2004; 94: 19–29.
- 189) Gaido ML, Cidlowski JA. Identification, purification, and characterization of a calcium-dependent endonuclease (NUC18) from apoptotic rat thymocytes. NUC18 is not histone H2B. *J Biol Chem*, 1991; 266: 18580–5.
- 190) Urbano A, McCaffrey R, Foss F. Isolation and characterization of NUC70, a cytoplasmic hematopoietic apoptotic endonuclease. *J Biol Chem*, 1998; 273: 34820–7.
- 191) Barry MA, Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. *Arch Biochem Biophys*, 1993; 300: 440–50.
- 192) Scovassi AI, Torriglia A. Activation of DNA-degrading enzymes during apoptosis. *Eur J Histochem*, 2003; 47: 185–94.
- 193) Sussin SA, Lorenzo HK, Zamzani N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. *Nature*, 1999; 97: 441–6.
- 194) Jiang W, Zahurak M, Goldenberg D, Milman Y, Park HL, Westra WH, Koch W, Sidransky D, Califano J. Increased plasma DNA integrity index in head and neck cancer patients. *Int J Cancer*, 2006; 119: 2673–6.
- 195) Wang BG, Huang Hy, Chen YC, Bristow RE, Kassaei K, Cheng CC, et al. Increased plasma DNA integrity in cancer patients. *Cancer Res*, 2003; 63: 3966–8.
- 196) Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. *Cancer Res*, 1977; 37: 646–50.
- 197) Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastro-intestinal disease. *Cancer*, 1983; 51: 2116–20.
- 198) Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. *Oncol*, 1989; 46: 318–22.
- 199) Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. *Clin Chem*, 2006; 52: 1062–9.
- 200) Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H, Taja-Chayeb L, García-López P, Segura-Pacheco B, et al. Circulating nucleosomes and response to chemotherapy: an *in vitro*, *in vivo* and clinical study on cervical cancer patients. *Int J Cancer*, 2003; 104: 663–8.

- 201) Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. *J Natl Cancer Inst*, 2002; 94: 1697-703.
- 202) Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. *Cancer Lett*, 2006; 243: 64-70.
- 203) Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, von Ruecker A, et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. *J Urol*, 2009; 181: 363-71.
- 204) Ellinger J, Bastian PJ, Ellinger N, Kahl P, Perabo FG, Büttner R, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. *Cancer Lett*, 2008; 264: 274-80.
- 205) Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. *Cancer Lett*, 2004; 205: 173-80.
- 206) Jin Z, El-deiry WS. Overview of cell death signaling pathways. *Cancer Biol Ther*, 2005; 4: 139-63.
- 207) Chiang PW, Beer DG, Wei WL, Orringer MB, Kurnit DM. Detection of erbB-2 amplification in tumors and sera from esophageal carcinoma patients. *Clin Cancer Res*, 1999; 5: 1381-6.
- 208) Deligezer U, Eralp Y, Akisik EE, Saip P, Topuz E, Dalay N. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. *Ann N Y Acad Sci*, 2008; 1137: 175-9.
- 209) Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YMD. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T cell lymphoma. *Clin Cancer Res*, 2002; 8: 29-34.
- 210) Elmore S. Apoptosis: A review of programmed cell death. *Toxicol Pathol*, 2007; 35: 495-516.
- 211) Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. *Clin Chem*, 2003; 49: 1958-65.
- 212) Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. *Scand J Urol Nephrol Suppl*, 2000; 82: 82-93.
- 213) Goessl C, Muller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. *Ann N Y Acad Sci*, 2001; 945: 51-8.
- 214) Hamdy FC. Prognostic and predictive factors in prostate cancer. *Cancer Treat Rev*, 2001; 27: 143-51.

- 215) Li K, Li Y, Shelton JM, Richardson JA, Spencer E, Chen ZJ, Wang X, Williams RS. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced apoptosis. *Cell*, 2000; 101: 389–99.
- 216) Kagan VE, Borisenko GG, Tyurina YY, Tyurin VA, Jiang J, Potapovich AI, et al. Oxidative lipidomics of apoptosis: redox catalytic interactions of cytochrome c with cardiolipin and phosphatidylserine. *Free Radic Biol Med*, 2004; 37: 1963–85.
- 217) Kagan, VE, Tyurin VA, Jiang J, Tyurina YY, Ritow VB, Amoscato AA. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. *Nat Chem Biol*, 2005; 1: 223–32.
- 218) Lee I, Salomon AR, Yu K, Doan JW, Grossman I, Hüttemann M. New prospects for an old enzyme: mammalian cytochrome c is tyrosine-phosphorylated *in vivo*. *Biochemistry*, 2006; 45: 9121–8.
- 219) Yu H, Lee I, Salomon AR, Yu K, Hüttemann M. Mammalian liver cytochrome c is tyrosine-48 phosphorylated *in vivo*, inhibiting mitochondrial respiration. *Biochim Biophys Acta*, 2008; 1777: 1066–71.
- 220) Zhao X, Leon IR, Bak S, Mogensen M, Wrzesinski K, Hojlund K, Jensen ON. Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. *Mol Cell Proteomics*, 2010.
- 221) Wang X. The expanding role of mitochondria in apoptosis. *Genes Dev*, 2001; 15: 2922–33.
- 222) Green DR. Apoptotic pathways: paper wraps stone blunts scissors. *Cell*, 2000; 102: 1–4.
- 223) Beresewic zM, Kowalczyk JE, Zablocka B. Cytochrome c binds to inositol (1, 4, 5) trisphosphate and ryanodine receptors *in vivo* after transient brain ischemia in gerbils. *Neurochem Int*, 2006; 48: 568–71.
- 224) Cao G, Xing J, Xiao X, Liou AK, Gao Y, Yin XM, et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. *J Neurosci*, 2007; 27: 9278–93.
- 225) Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. *Science*, 1997; 275: 1129–32.
- 226) Twiddy D, Brown DG, Adrain C, Jukes R, Martin SJ, Cohen GM, et al. Pro-apoptotic proteins released from the mitochondria regulate the protein composition and caspase-processing activity of the native Apaf-1/caspase-9 apoptosome complex. *J Biol Chem*, 2004; 279: 19665–82.
- 227) Martin MC, Allan LA, Lickrish M, Sampson C, Morrice N, Clarke PR. Protein kinase A regulates caspase-9 activation by Apaf-1 downstream of cytochrome c. *J Biol Chem*, 2005; 280: 15449–55.

- 228) Hancock JT, Desikan R, Neill SJ. Does the redox status of cytochrome c act as a fail-safe mechanism in the regulation of programmed cell death?. *Free Radic Biol Med*, 2001; 3: 1697–703.
- 229) Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. *Nat Rev Mol Cell Biol*, 2007; 8: 405–13.
- 230) Fadeel B, Ottosson A, Pervaiz S. Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance. *Cell Death Differ*, 2008; 15: 443–52.
- 231) Kim HE, Du F, Fang M, Wang X. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. *Proc Natl Acad Sci USA*, 2005; 102: 17545–50.
- 232) Filomeni G, Ciriolo MR. Redox control of apoptosis: an update. *Antioxid Redox Signal*, 2006; 8: 2187–92.
- 233) Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. *Antioxid Redox Signal*, 2005; 7: 472–81.
- 234) Yu T, Wang X, Purring-Koch C, Wei Y, McLendon G. A mutational epitope for cytochrome c binding to the apoptosis protease activation factor-1. *J Biol Chem*, 2001; 276: 13034–8.
- 235) Olteanu A, Patel C, Dedmon M, Kennedy S, Linhoff M, Minder C, et al. Stability and apoptotic activity of recombinant human cytochrome c. *Biochem Biophys Res Commun*, 2003; 312: 733–40.
- 236) Chandra D, Bratton SB, Person MD, Tian Y, Martin AG, Ayres M, et al. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome c and inhibiting apoptosome. *Cell*, 2006; 125: 1333–46.
- 237) Basova LV, Kurnikov IV, Wang L, Ritov VB, Belikova NA, Vlasova II, et al. Cardiolipin switch in mitochondria: shutting off the reduction of cytochrome c and turning on the peroxidase activity. *Biochem*, 2007; 46: 3423–34.
- 238) Jiang J, Serinkan BF, Tyurina YY, Borisenko GG, Mi Z, Robbins PD, et al. Peroxidation and externalization of phosphatidylserine associated with release of cytochrome c from mitochondria. *Free Radic Biol Med* 2003; 35: 814–25.
- 239) D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. *Cancer Journal for Clinician*, 2000; 55: 319–21.
- 240) D'Agostini F, Izzotti A, Balansky RM, Bennicelli C, De Flora S. Modulation of apoptosis by cancer chemopreventive agents. *Mutation Res*, 2005; 59: 173–86.
- 241) National Institutes of Health Office of Dietary Supplements. Dietary supplement fact sheets. [http://ods.od.nih.gov/Health Information/Information About Individual Dietary Supplements.aspx](http://ods.od.nih.gov/Health%20Information/Information%20About%20Individual%20Dietary%20Supplements.aspx) [accessed April 19, 2010].

- 242) Mignone LI, Giovannucci E, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, et al. Dietary carotenoids and the risk of invasive breast cancer. *Int J Cancer*, 2009; 124: 2929–37.
- 243) Dennehy C, Tsourounis C. A review of select vitamins and minerals used by postmenopausal women. *Maturitas*, 2010; 66: 370–80.
- 244) Peterson PA. Studies on the interaction between prealbumin, retinol-binding protein, and vitamin A. *J Biol Chem*, 1971; 246: 44–9.
- 245) Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. *Science*, 2007; 315: 820–5.
- 246) Wu BX, Moiseyev G, Chen Y, Rohrer B, Crouch RK, Ma JX. Identification of RDH10, an all-trans retinol dehydrogenase, in retinal Müller cells. *Invest Ophthalmol Vis Sci*, 2004; 45: 3857–62.
- 247) Niederreither K, Subbarayan V, Dollé P, Chambon P. Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. *Nat Genet*, 1999; 21: 444–8.
- 248) Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. *Cell Mol Life Sci*, 2010; 67: 1423–45.
- 249) Napoli JL. Retinoic acid biosynthesis and metabolism. *FASEB J*, 1996; 10: 993–1001.
- 250) Levin MS. Cellular retinol-binding proteins are determinants of retinol uptake and metabolism in stably transfected caco-2 cells. *J Biol Chem*, 1993; 268: 8267–76.
- 251) Delva L, Bastie JN, Rochette-Egly C, Kraïba R, Balitrand N, Despouy G, et al. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. *Mol Cell Biol*, 1999; 19: 7158–67.
- 252) Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. *Journal of Cystic Fibrosis*, 2008; 7: 137–41.
- 253) Ghyselinck NB, Bavik C, Sapin V, Mark M, Bonnier D, Hindelang C, et al. Cellular retinol-binding protein I is essential for vitamin A homeostasis. *EMBO J*, 1999; 18: 4903–14.
- 254) Chapman MS. Vitamin A: History, Current Uses, and Controversies. *Semin Cutan Med Surg*, 2012; 31: 11-6.
- 255) Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: All-trans retinoic acid down-regulates TLR2 expression and function. *J Immunol*, 2005; 174: 2467-70.

- 256) Oeff MK, Seltsmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, et al: Differential regulation of Toll-like receptor and CD 14 pathways by retinoids and corticosteroids in human sebocytes. *Dermatol*, 2006; 213: 266.
- 257) Kirschner R, Rother K, Müller GA, Engeland K. Regulation of vitamin metabolism by p53 and p63 in development and cancer. *Cell Cycle*, 2010; 9: 2177–88.
- 258) Simoni D, Tolomeo M. Retinoids, apoptosis and cancer. *Curr Pharm Des*, 2001; 7: 1823–37.
- 259) Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and ovarian cancer. *J Cell Physiol*, 2000; 18: 1–20.
- 260) Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. *Leukemia*, 2002; 16: 463–72.
- 261) Dorjgochoo T, Gu K, Kallianpur A, Chen Z, Zheng W, Lu W, et al. Menopausal symptoms among breast cancer patients 6 months after diagnosis: a report from the Shanghai Breast Cancer Survival Study. *Menopause*, 2009; 16: 1205–12.
- 262) Wang C, Baumgartner RN, Yang D, Slattery ML, Murtaugh MA, Byers T, et al. No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-Hispanic White women. *Breast Cancer Res Treat*, 2009; 114: 137–45.
- 263) Epplein M, Shvetsov YB, Wilkens LR, Franke AA, Cooney RV, Le Marchand L, et al. Plasma carotenoids, retinol, and tocopherols and postmenopausal breast cancer risk in the Multiethnic Cohort Study: a nested case-control study. *Breast Cancer Res*, 2009; 11: 1-7.
- 264) Kabat GC, Kim M, Adams-Campbell LL, Caan BJ, Chlebowski RT, Neuhauser ML, et al. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. *Am J Clin Nutr*, 2009; 90: 162–9.
- 265) Formelli F, Meneghini E, Cavadini E, Camerini T, Di Mauro MG, De Palo G, et al. Plasma retinol and prognosis of postmenopausal breast cancer patients. *Cancer Epidemiol Biomarkers Prev*, 2009; 18: 42–8.
- 266) Hultén K, Van Kappel AL, Winkvist A, et al. Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in northern Sweden. *Cancer Causes Control* 2001; 12: 529–37.
- 267) Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women’s Health Initiative Observational Study. *Am J Clin Nutr*, 2008; 87: 1009–18.
- 268) Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. *Cell*, 2005; 122: 835–47.

- 269) Kogai T, Kanamoto Y, Che LH, Taki K, Moatamed F, Schultz JJ, et al. Systemic retinoic acid treatment induces sodium /iodide symporter expression and radioiodide uptake in mouse breast cancer models. *Cancer Res*, 2004; 64: 415 – 22.
- 270) Lim SJ, Paeng JC, Kim SJ, Kim SY, Lee H, Moon DH. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment. *J Nucl Med*, 2007, 48: 398– 404.
- 271) Pazdro R, Burgess RJ. The role of vitamin E and oxidative stress in diabetes complications. *Mechanisms of Ageing and Development*, 2010; 131: 276–86.
- 272) Zingg JM. Modulation of signal transduction by vitamin E. *Mol Aspects Med*, 2007; 28: 5–6.
- 273) Sen CK, Khanna S, Roy S. Tocotrienols in health and disease: the other half of the natural vitamin E family. *Mol Aspects Med*, 2007; 28: 692–728.
- 274) Meydani M, Koga T, Ali S. Vitamin E deficiency. *Encyclopedia of Life Sciences Nature*, 2001: 1–6.
- 275) Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, et al . New perspectives on vitamin E: α -tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. *Free Radic Biol Med*, 2004; 36: 1–15.
- 276) Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. *J Pediatr*, 1999; 135: 601-10.
- 277) Papas AM. Vitamin E: A New Perspective. *NUTRI News*, 2008: 1-8.
- 278) Porta EA. Dietary factors in lipofuscinogenesis and ceroidogenesis. *Arch Gerontol Geriatr*, 2002; 34: 319–27.
- 279) Ezaki Y, Nishihara E, Shibata Y, Matsuo T, Kitagawa N, Nagata I, et al. Vitamin E prevents the neuronal cell death by repressing cyclooxygenase-2 activity. *Neuro report* , 2005; 16: 1163– 7.
- 280) Hyland S, Muller D, Hayton S, Stoecklin E, Barella L. Cortical gene expression in the vitamin E-deficient rat: possible mechanisms for the electrophysiological abnormalities of visual and neural function. *Ann Nutr Metab*, 2006; 50: 433–41.
- 281) Stolzing A, Widmer R, Jung T, Voss P, Grune T. Tocopherol-mediated modulation of age-related changes in microglial cells: Turnover of extracellular oxidized protein material. *Free Radic Biol Med*, 2006; 40: 2126–35.
- 282) Cecchini T, Ciaroni S, Ferri P, Ambrogini P, Cuppini R, Santi S, et al. α -Tocopherol, an exogenous factor of adult hippocampal neurogenesis regulation. *J Neurosci Res*, 2003; 73: 447–55.

- 283) Zingg JM. Vitamin E: An overview of major research directions. *Molecular Aspects of Medicine*, 2007; 28: 400–22.
- 284) Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. *Free Radic Biol*, 2007; 43: 4–15.
- 285) Azzi A. Molecular mechanism of a-tocopherol action. *Free Radic Biol Med*, 2007; 43: 16–21.
- 286) Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. *Cur Med Chem*, 2004; 11 : 1113–33.
- 287) Villacorta L, Azzi A, Zingg JM. Regulatory role of vitamin E and C on extracellular matrix components of the vascular system. *Mol Aspects Med*, 2007; 28: 507–37.
- 288) Munteanu A, Zingg JM. Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. *Mol Aspects Med*, 2007; 28: 538–90.
- 289) Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, et al. Vitamins E and C are safe across a broad range of intakes. *Am J Clin Nutr*, 2005; 81: 736–45.
- 290) Brigelius-Flohe R. Induction of drug metabolizing enzymes by vitamin E. *J Plant Physiol*, 2005; 162: 797–802.
- 291) Coulter ID, Hardy ML, Morton SC, Hilton LG, Tu W, Valentine D, et al. Antioxidants vitamin C and vitamin E for the prevention and treatment of cancer. *J Gen Intern Med*, 2006; 21: 735–44.
- 292) Kline K, Yu W, Sanders BG. Vitamin E and breast cancer. *J Nutr*, 2004; 134: 3458– 62.
- 293) Ricciarelli R, Argellati F, Pronzato MA, Domenicotti C. Vitamin E and neurodegenerative disease. *Mol Aspects Med*, 2007; 28: 591–606.
- 294) Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal NT, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. *Am J Clin Nutr*, 2005; 81: 508–14.
- 295) Fariss MW, Zhang JG. Vitamin E therapy in Parkinson's disease. *Toxicol*, 2003; 189: 129– 46.
- 296) Mariotti C, Gellera C, Rimoldi M, Mineri R, Uziel G, Zorzi G, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. *Neurol Sci*, 2004; 25: 130–7.
- 297) Constantinou C, Papas A, Constantinou A. Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. *Int J Cancer*; 2008; 123:739–52.
- 298) Sylvester PW, Theriault A. A role of tocotrienols in the prevention of cardiovascular disease and breast cancer. *Curr Top Nutraceutical Res*, 2003; 1: 121–36.

- 299) Friderich MJ. To “E” or not to “E”, vitamin E’s role in health and disease is the question. *JAMA*, 2004; 292: 671–3.
- 300) Chang PN, Yap WN, Lee DT, Ling MT, Wong YC, Yap YL. Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. *Nutr Cancer*, 2009; 61: 357–66.
- 301) Hussein D, Mo H. d-Delta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells. *Pancreas*, 2009; 38: 124–36.
- 302) Weng-Yew W, Selvaduray KR, Ming CH, Nesaretnam K. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. *Nutr Cancer*, 2009, 61, 367–73.
- 303) Kashiwagi K, Harada K, Yano Y, Kumadaki I, et al. A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells. *Biochem Biophys Res Commun*, 2008; 365: 875–81.
- 304) Kashiwagi K, Virgona N, Harada K, Kido W. et al. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. *Life Sci*, 2009; 84: 650–6.
- 305) Nesaretnam K. Multitargeted therapy of cancer by tocotrienols: mini review. *Cancer Letters*, 2008; 269: 388–95.
- 306) Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, et al. Total and cancer mortality after supplementation with vitamins and minerals: Follow-up of the linxian general population nutrition intervention trial. *J Natl Cancer Inst*, 2009; 101: 507 – 18.
- 307) Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. *European Journal of Cancer*, 2004; 40: 1713-23.
- 308) Kolomeki K, Maciaszczyk P, Stepień H, Stepień T, Kuzdak K. P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant tumours. *Bratisl Lek listy*, 2005; 106: 297-300.
- 309) Krepela E, Dankova P, Moravcikova E, Krepelova A, Prochazka J, Cermak J, Schützner J, et al. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. *International J of Oncol*, 2009; 35: 1449-62.
- 310) Kavathia N, Jain A, Walston J, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. *AGING*, 2009; 1:7.
- 311) Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. *Science*, 1998; 282: 290-3.

- 312) Chard T. An introduction to radioimmunoassay & related techniques, 4th Ed, 1990. Amsterdam, Elsevier.
- 313) Andrea Renz, Wolfgang E. Berdel, Michael Kreuter, Claus Belka, Klaus Schulze-Osthoff and Marek Los. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death *in vivo*. *Blood*, 2001; 98: 1542-48.
- 314) Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. *Sur Oncol*, 2012; 21: 125-31.
- 315) Signore M, Ricci-Vitiani L, De Maria R. Targeting apoptosis pathways in cancer stem cells. *Cancer Letters*, 2011.
- 316) Pierpaoli E, Viola V, Pilolli F, Piroddi M, Galli F, Provinciali M. γ - and δ -tocotrienols exert a more potent anticancer effect than α -tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. *Life Sciences*, 2010; 86: 668 –75.
- 317) Lee J, GuW. The multiple levels of regulation by p53 ubiquitination. *Cell Death and Differentiation*, 2010; 17: 86–92.
- 318) Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. *Br J Cancer*, 2007; 96: 639-45.
- 319) Wang C, Youle RJ. The role of mitochondria in apoptosis. *Annu Rev Genet*, 2009; 43: 95–118.
- 320) Mittal N, Sanyal SN. Therapeutic role of surfactant during mitochondrial membrane mediated apoptosis in endotoxin-induced acute respiratory distress syndrome. *Am J Biomed Sci*, 2012; 4: 60-9.
- 321) Catarino R, Ferreira MM, Rodrigues H, Coelho A, Noyal A, Sousa A, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. *DNA and Cell Biology*, 2008; 27: 415–21.
- 322) Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. *Molecular Cancer*, 2009; 8: 105.
- 323) Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. *Biochemical Pharmacology*, 2011; 82: 427–34.
- 324) Chu KJ, Lai EC, Yao XP, Zhang HW, Lau WY, Fu XH. Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation—A systematic review and meta-analysis. *Asian J Surg*, 2010; 33:120–6.
- 325) Stone WL, Campbell SE, Krishnan K. The role of vitamin E in prostate cancer. In: D.R. Spitz et al. (eds.), *Oxidative stress in cancer biology and therapy, Oxidative stress in applied basic research and clinical practice*, Springer Science+Business Media, 2012: 333-54.

- 326) Molin SC, Ruzicka T. Retinoids. In: Rustemeyer T, Elsner P, John SM, Maibach HI (eds.). Springer-Verlag Berlin Heidelberg, 2012: 1023-34.
- 327) Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, et al. The TP53 status and response to chemotherapy in breast cancer, *Pathobiology*, 2008; 75: 132–9.
- 328) Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. *PLoS One*, 2008; 3: 3062.
- 329) Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. *Oncogene*, 2007; 26 : 1306–16.
- 330) Varna M, Lehmann J, Che E, Turpin C, et al. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. *International J of Cancer*, 2009; 124: 991–97.
- 331) He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, et al. Induction of p21 by p53 following DNA damage inhibits both Cdk 4 and Cdk2 activities. *Oncogene*, 2005; 24: 2929–43.
- 332) Cox ML, Meek DW. Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. *Cellular Signalling*, 2010; 22: 564–71.
- 333) Laptenko O, Prives C. Transcriptional regulation by p53: one protein Many possibilities. *Cell Death Differ*, 2006; 13: 951– 61.
- 334) Chumakov PM. Versatile functions of p53 protein in multicellular organisms. *Biochemistry*, 2007; 72: 1399–421.
- 335) Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. *Nat Rev Cancer*, 2009; 9: 724–37.
- 336) Schwartz J, Shklar G, Trickler D. p53 in the anticancer mechanism of vitamin E. *Oral Oncol Eur J Cancer*, 1993; 29: 313 –18.
- 337) Zhang L, Yan L, Zhang Y, Wu N, Shen Y. Role of Acetylated p53 in Regulating the Expression of map2 in Retinoic Acid-induced P19 Cells. *Chin Med Sci J*, 2010; 25: 71-5.
- 338) Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. *J Cell Biol*, 2006; 173: 533-44.

- 339) Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both *in vitro* and *in vivo*. *Proc Natl Acad Sci USA*, 2004; 101: 2259-64.
- 340) Li F, Ling X. survivin study: an update of "what is the next wave"? *J Cell Physiol*, 2006; 208: 476-86.
- 341) Altieri DC. Validating survivin as a cancer therapeutic target. *Nat Rev Cancer*. 2003; 3: 46-54.
- 342) Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. *J Clin Oncol*, 2008; 26: 2568-81.
- 343) Ahn KS, Sethi G, Krishnan K, Aggarwal BB. Gamma-tocotrienol inhibits nuclear factor-kappa B signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. *J Biol Chem*, 2007; 282:809–20.
- 344) Patacsil D, Osayi S, Tran AT, Saenz F, Yimer L, Shajahan AN, et al. Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. *Genes Nutr*, 2012; 7: 83–9.
- 345) Chi HT, Ly BT, Taguchi T, Watanabe T, Sato Y. All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein. *J of Experim & Clin Cancer Res*, 2010; 29: 165-72.
- 346) Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, et al. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. *J of Experim & Clin Cancer Res*, 2008; 27: 37-44.
- 347) Kugawa F. et al. Evaluation of cell death caused by CDF (cyclophosphamide, doxorubicin, 5-fluorouracil) multi-drug administration in the human breast cancer cell line MCF-7. *Biol Pharm Bull*, 2004; 27: 392–8.
- 348) Rickmann M, Vaquero EC, Malagelada JR, Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. *Gastroenterol*, 2007; 132: 2518–32.
- 349) Srivastava JK, Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. *Biochem Biophys Res Commun*, 2006; 346: 447–53.

- 350) Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. *Cell Cycle*, 2004; 3: 205–11.
- 351) Campbell S, Stone W, Whaley S, Krishnan K. Development of gamma tocopherol as a colorectal cancer chemopreventive agent. *Crit Rev Oncol Hematol*, 2003; 47: 249–59.
- 352) Engedal N, Auberger P, Blomhoff HK. Retinoic acid regulates Fas-induced apoptosis in Jurkat T cells: reversal of mitogen-mediated repression of Fas DISC assembly. *Journal of Leukocyte Biol*, 2009; 85: 469-80.
- 353) Stennicke HR, Jurgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, et al. Procaspase-3 is a major physiologic target of caspase-8. *J Biol Chem*, 1998; 273: 27084 – 90.
- 354) Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, 3, 6, 7, 8, and -10 in a caspase-9-dependent manner. *J Cell Biol*, 1999; 144: 281– 92.
- 355) Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. *J Biol Chem*, 1999; 274: 30651–6.
- 356) Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W. Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. *Br J Nutr*, 2008; 99: 1247–54.
- 357) Xu WL, Liu JR, Liu HK, Qi GY, Sun XR, Sun WG, et al. Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells. *Nutrition*, 2009; 25: 555–66.
- 358) Sakai M, Okabe M, Tachibana H, Yamada K. Apoptosis induction by gamma-tocotrienol in human hepatoma Hep3B cells. *J Nutr Biochem*, 2006; 17: 672–6.
- 359) Renuka Devi R, Arumughan C. Antiradical efficacy of phytochemical extracts from defatted rice bran. *Food Chem Toxicol*, 2007; 45: 2014–21.
- 360) Shah SJ, Sylvester PW. Tocotrienol-induced cytotoxicity is unrelated to mitochondrial stress apoptotic signaling in neoplastic mammary epithelial cells. *Biochem Cell Biol*, 2005; 83: 86–95.
- 361) Sylvester PW, Shah S. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. *Asia Pac J Clin Nutr*, 2005; 14: 366–73.

- 362) Sun W, Xu W, Liu H, Liu J, Wang Q, Zhou J, et al. gamma-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. *J Nutr Biochem*, 2009; 20: 276–84.
- 363) Cui Y, Lu Z, Bai L, Shi Z, Zhao W, Zhao B. β -Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor expression and reactive oxygen species production in MCF-7 cancer cells. *EUROPEAN JOURNAL OF CANCER*, 2007; 43: 2590–601.
- 364) Weber T, Dalen H, Andera L, Nègre-Salvayre A, Augé N, Sticha M, et al. Mitochondria play a central role in apoptosis induced by α -tocopheryl succinate, an agent with anticancer activity: comparison with receptor-mediated pro-apoptotic signaling. *Biochemistry*, 2003; 42: 4277–91.
- 365) Wang XF, Dong LF, Zhao Y, Tomasetti M, Wu K, Neuzil J. Vitamin E analogues as anti-cancer agents: lessons from studies with α -toco-pheryl succinate. *Mol Nutr Food Res*, 2006; 50: 675–85.
- 366) Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. Gamma-tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. *Proc Natl Acad Sci USA*, 2004; 101: 17825–30.
- 367) Bezombes C, Laurent G, Jaffrezou JP. Implication of raft microdomains in drug induced apoptosis. *Curr Med Chem Anticancer Agents*, 2003; 3: 263–70.
- 368) Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. *Oncogene*, 2003; 22: 7070–7.
- 369) Geeraert L, Mannaerts GP, van Veldhoven PP. Conversion of dihydroceramide into ceramide: involvement of a desaturase. *Biochem J*, 1997; 327: 125–32.
- 370) Stiban J, Fistere D, Colombini M. Dihydroceramide hinders ceramide channel formation: implications on apoptosis. *Apoptosis*, 2006; 11: 773–80.
- 371) Palozza P, Serini S, Torsello A, Maggiano N, Ranelletti FO, Wolf FI, et al. Mechanism of activation of caspase cascade during beta-carotene- induced apoptosis in human tumor cells. *Nutr C ancer*, 2003; 47: 76–87.



obeyikanda.com